

DOCKET NO: ISIS0124-100 (RTS-0739US)

PATENT

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please cancel claims 9, 14, 17-20, 22, 23, 26, 27, 29, and 30 without prejudice to their presentation in another application, and amend claims 1, 13, 24 and 25 as follows.

1. (currently amended) An antisense compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding ACE2 (SEQ ID NO:4), wherein said compound is at least 70% at least 85% complementary to said nucleic acid molecule encoding ACE2 (SEQ ID NO:4), wherein said compound comprises at least one 2'-O-methoxyethyl sugar moiety and wherein said compound inhibits the expression of ACE2 mRNA by at least 10%.
2. (original) The antisense compound of claim 1 comprising 12 to 50 nucleobases in length.
3. (original) The antisense compound of claim 2 comprising 15 to 30 nucleobases in length.
4. (original) The antisense compound of claim 1 comprising an oligonucleotide.
5. (original) The antisense compound of claim 4 comprising a DNA oligonucleotide.
6. (original) The antisense compound of claim 4 comprising an RNA oligonucleotide.
7. (original) The antisense compound of claim 4 comprising a chimeric oligonucleotide.
8. (original) The antisense compound of claim 4 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex.
9. (cancelled).

DOCKET NO: ISIS0124-100 (RTS-0739US)

PATENT

10. (original) The antisense compound of claim 1 having at least 90% complementarity with said nucleic acid molecule encoding ACE2.

11. (original) The antisense compound of claim 1 having at least 95% complementarity with said nucleic acid molecule encoding ACE2.

12. (original) The antisense compound of claim 1 having at least 99% complementarity with said nucleic acid molecule encoding ACE2.

13. (currently amended) The antisense compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.

14. (cancelled).

15. (original) The antisense compound of claim 1 having at least one phosphorothioate internucleoside linkage.

16. (original) The antisense compound of claim 1 wherein at least one cytosine is a 5-methylcytosine.

17-20. (cancelled).

21. (original) A kit or assay device comprising the antisense compound of claim 1.

22-23. (cancelled).

24. (currently amended) The antisense compound of claim 1, wherein said antisense compound comprises at least an 8-nucleobase portion of SEQ ID NOs NOS 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 26, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 40, 42, 43, 45, 46, 49, 50, 51, 52, 53, 55,

DOCKET NO: ISIS0124-100 (RTS-0739US)

PATENT

56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 76, 77, 78, 80, 82, 86, 88, 89  
or 90.

25. (currently amended) The antisense compound of claim 24, wherein said antisense compound has a sequence selected from the group consisting of SEQ ID NOs NOS 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 26, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 40, 42, 43, 45, 46, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 76, 77, 78, 80, 82, 86, 88, 89 and 90.

26-27. (cancelled).

28. (original) The antisense compound of claim 1, wherein said antisense compound comprises an antisense nucleic acid molecule that is specifically hybridizable with a coding region of a nucleic acid molecule encoding ACE2.

29-30. (cancelled).